StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$6.88−0.14 (-1.99%)

Close on Nov 18, 2026Market cap $249.69MP/E –Yield –

Evommune gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Evommune

Evommune has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Evommune figures

See a number that looks wrong?